岱山县海水养殖贝类重金属含量检测

我县是个海岛县,养殖业发达,特别是贝类养殖.大量投放市场和出口,供人们食用.由于近年来海洋环境污染严重,使养殖贝类重金属等有毒物质含量增高,对人体有毒害作用.为了解我县养殖贝类的重金属含量情况,对某些养殖贝类进行了铅、砷、镉、汞、铜、锌等6个项目的检测分析,现报告如下.     

Cajal间质细胞在先天性巨结肠和巨结肠同源病结肠中的分布研究

目的研究先天性巨结肠（Hirschsprung’s disease，HD）和巨结肠同源病（allied Hirschsprung’s disease，AHD）肠壁内Cajal间质细胞（interstitial cells of Cajal，ICCs）的分布状态，探讨HD和AHD的发病机制。方法选择确诊为HD和AHD的患者各20例，取巨结肠根治术吻合口远端的全层肠壁作为实验组，另取16例正常结肠标本作为对照组。用鼠抗人c—kit单克隆抗体（CD117）标记ICCs，Image Pro-Plus图像分析系统检测ICCs。结果对照组中大量ICCs分布在肌间神经丛周围和环纵肌层内，ICCs包绕神经丛周围，肌层间ICCs连续分布；HD组远端肠管中肌层间和各肌层内ICCs明显减少甚至缺如，与对照组比较差异有统计学意义，P〈0．01；AHD组远端肠管中神经丛大小不一，ICCs分布差异大，大多数神经丛区ICCs减少，环肌层内ICCs明显减少，与AHD组和对照组比较差异有统计学意义，P〈0.01。HD组远端结肠中ICCs减少比AHD组显著，差异有统计学意义，P〈0．01。结论HD、AHD病变肠管中除了神经节细胞的异常外，同时存在ICCs异常；ICCs在HD和AHD的分布不同可能与两者临床症状差异有关；肠管中ICCs数量可能与临床症状及预后有一定关系。     

蛇足石杉内生真菌2F09P03B产石杉碱甲发酵条件的研究

 目的 研究发酵条件对蛇足石杉支顶孢属内生真菌2F09P03B 石杉碱甲生成的影响，并探讨发酵条件的优化。 方法 通过测定 2F09P03B 生长曲线、石杉碱甲积累曲线和培养液 pH 值随时间的变化情况，了解该菌株的培养特性；考察不同碳源和氮源对石杉碱甲积累的影响。在单因素试验的基础上，利用正交试验优化培养基碳源、氮源组成；考察 MgSO4、KH2PO4、NaCl、CaSO4 对石杉碱甲生成的影响，确定无机盐组成；优化接种量、发酵时间、培养温度、摇床转速等发酵工艺条件。 结果 菌株 2F09P03B 的最佳培养基组成为：马铃薯 150 g/L，玉米粉 30 g/L，麦芽糖 25 g/L，酵母膏 10 g/L，麸皮 30 g/L，KH2PO4 1.5 g/L，MgSO4 0.5g/L，NaCl 0.3 g/L，CaSO4 0.3 g/L，pH 自然；最佳发酵工艺条件为：接种量 8%，发酵时间 10 d，培养温度 28 ℃，摇床转数 140 r/min。在此条件下，发酵液中石杉碱甲含量为 8.17 μg/L，最高达到 8.32 μg/L，约为其干重的 0.07% 左右。 结论 发酵条件对菌株 2F09P03B 石杉碱甲产量有明显影响。优化后的发酵条件可使该菌株石杉碱甲产量明显提高，有望成为石杉碱甲新药源。     

重组人内皮抑素腺病毒抗肿瘤实验研究

目的肿瘤生长具有血管依赖性。内皮抑素为胶原X羧基末端裂解片段,是重要的内源性血管抑制因子。实验中利用重组人内皮抑素腺病毒(recombinanthumanendostatinadenorirus,Ad-hEndo)在肿瘤局部给药以探索其抗血管基因治疗的可行性。方法以Ad-hEndo感染体外培养肿瘤细胞,观察重组蛋白表达及其对培养的血管内皮细胞的抑制效应;在裸鼠A549肺癌模型中瘤内注射重组病毒,观察肿瘤抑制效应、剂量依从效应和毒副反应。结果不同感染复数的Ad-hEndo感染肿瘤细胞均表达重组内皮抑素蛋白,并能抑制血管内皮细胞的生长。动物实验中Ad-hEndo治疗组肿瘤体积及肺转移结节数明显低于对照组,且转移数与治疗剂量负相关。结论以腺病毒为载体的肿瘤局部血管基因治疗能抑制肿瘤新生血管形成进而有效抑制肿瘤生长和转移,其效应具有剂量依从性。     

定志小丸对抑郁模型大鼠海马神经干细胞Nestin表达的影响

目的观察定志小丸对抑郁大鼠海马神经干细胞的影响.方法采用慢性不可预见性应激造成大鼠抑郁模型,Openfield法测定行为学,HE染色观察海马神经元形态学,免疫组织化学技术检测Nestin表达.结果抑郁模型大鼠的行为学得分明显降低,海马神经元数量减少,形态异常,Nestin表达少,而定志小丸组海马神经元数量和形态无明显变化,Nestin表达增加.结论定志小丸对海马神经元具有保护作用,能够诱导神经干细胞增殖.     

后矢状位肛门直肠成形术后便秘原因初探

目的　研究无肛畸形胎鼠直肠盲端神经元细胞分布情况 ,探讨后矢状位肛门直肠成形术 (PSARP)后便秘发生原因。方法　选用 2～ 3个月龄 ,体重 2 5 0～ 30 0g健康Wistar大白鼠 12只 ,其中雌鼠 8只 ,雄鼠 4只。实验组雌鼠为 5只 ,对照组为 3只。雌雄交配后第 11d对实验组 5只雌鼠使用乙烯硫脲 (ethylenethiourea ,ETU)灌胃 (1%乙烯硫脲溶液 ,12 5mg/kg) ,对照组孕鼠在同一天使用等量蒸馏水灌胃。第 2 2d对两组孕鼠剖宫取胎 ,形态学研究取实验组及对照组各一只孕鼠 ,获实验组无肛胎鼠 6只 ,正常 5只 ,对照组胎鼠 10只。对胎鼠盆腔进行正中矢状切片 ,HE染色后在光镜下观察其形态。免疫组化研究将两组剩余孕鼠 (实验组 4只 ,对照组 2只 ) ,获胎鼠实验组无肛、正常和对照组各 2 7只、16只和 2 1只 ,取胎鼠直肠盲端 ,利用神经元特异性烯醇化酶 (neuronspecificenolaseNSE)和S 10 0蛋白标记肠壁内源性神经元细胞及胶质细胞 (SP)法 ,分别对肌间神经元、粘膜下神经元及胶质细胞进行计数并与对照组对比 ,进行统计学分析。结果　实验组无肛胎鼠盆腔正中矢状切面可显示直肠盲端的形态。直肠盲端与对照组直肠肌间神经元细胞数分别为 2 .0 9± 0 .5 0 ,2 .74±0 .5 1;直肠盲端与对照组直肠粘膜下神经元细胞数分别为 0 .72     

Impact of prolonged dual antiplatelet therapy on patients after drug-eluting stents implantation

Background Impact of dual antiplatelet therapy beyond 12 months on patients implanted with DES remains unsolved.Methods From January 2010 to June 2011,1873 patients who have been taking DAPT and free from death,myocardial infarction,stroke,repeat coronary revascularization,stent thrombosis,and major or minor bleeding according to TIMI criteria for 12 months after implantation of DES were randomly assigned to continuous (prolonged DAPT group) or discontinuous (standard DAPT group) clopidogrel (75 mg/day).The primary outcome was major adverse cardiovascular events (MACEs) which compose of death,nonfatal myocardial infarction (MI),nonfatal stroke,target vessel revascularization (TVR) or stent thrombosis (ST) at 180 days.Results There was no significant difference in the incidence of 180-day MACEs between prolonged DAPT group and standard DAPT group (8.98 % versus 10.13 %,respectively,P=0.400).The frequency of major bleeding was 0.64 % in prolonged DAPT arm and 0.43% in standard DAPT arm (P=0.523),that of minor bleeding was 3.32 % versus 2.87 % (P=0.585),respectively.Conclusions Prolonged DAPT beyond 12 months neither improve prognosis nor increase risk of bleeding in patients implanted with DES.     

Comparison of benefit and safety between different loading dose of clopidogrel on elderly patients undergoing primary percutaneous cronary intervention for ST-segment elevation myocardial infarction

Background Despite the proven benefit of 600-mg loading dose of clopidogrel in patients with acute ST-segment elevation myocardial infarction (STEMI) who undergo primary percutaneous cronary intervention (PCI), there is still concern about its benefit and safety on elderly population. Methods Data of 172 consecutive elderly patients (≥75 years) with STEMI who underwent primary PCI at Guangdong Provincial Cardiovascular Institute from January 2008 to December 2011 were retrospectively collected. Patients were divided into 600-mg loading clopidogrel group and 300-mg clopidogrel group accoring to the loading dose of clopidogrel before primary percunaeous coronary intervention(PCI). Enzymatic myocardial infarction size estimated by peak creatine kinase-myocardial band (CK-MB) and patency of the infarct-related artery (IRA) were compared. Thirty-day major adverse cardiac events (MACEs), which consist of death, nonfatal myocardial infarction (MI), nonfatal stroke, target vessel revascularization (TVR) or stent thrombosis (ST) were compared to assess the efficacy of different loading dose. Bleeding information was compared as well to assess the safety of different pretreatment stragety before primary PCI. Results 96 patients were adminstered with 600-mg loading clopidogrel before primary PCI while 76 were administered with 300-mg. Patency of the IRA was significantly higher in patients administered with 600-mg loading clopidogrel therapy as compared with those who received 300-mg loading clopidogrel (94.8% vs. 85.5%, P = 0.038). 600-mg loading dose of clopidogrel was associated with lower incidence of 30-day MACEs compared with 300-mg loading dose of clopidogrel (8.3% vs. 19.7%, P = 0.029) while did not increase the risk of TIMI major (3.1% vs. 3.9%, P = 0.770) and minor bleeding (10.4% vs. 6.6%, P = 0.376). Conclusion 600-mg loading clopidogrel improves final patency of the IRA and clinical outcome as compared with 300-mg loading clopidogrel without increasing bleeding hazard.     

LDL cholesterol as a novel risk factor for contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention

Background: Low density lipoprotein cholesterol (LDL-C) is associated with endothelial dysfunction, inflammation and increased vasoconstriction, which are involved in the development of contrast-induced acute kidney injury (CI-AKI). However, whether LDL-C is an independent risk factor of CI-AKI in patients undergoing percutaneous coronary intervention (PCI) is unknown. Methods: We prospectively enrolled 3236 consecutive patients undergoing PCI between January 2010 and September 2012. Multivariate logistic regression analysis was used to determine whether LDL-C is an independent risk factor of CI-AKI. CI-AKI was defined as an absolute increase in serum creatinine of ≥0.5 mg/dL or ≥25% over the baseline value within 48–72 h after contrast exposure. Results: CI-AKI was observed in 338 patients (10.4%). Patients with CI-AKI had a significantly higher rate of in hospital mortality (4.4% vs. 0.5%, p < 0.001), and significantly higher rates of other in hospital complications compared with those without CI-AKI. The LDL-C quartiles were as follows: Q1 (<2.04 mmol/L), Q2 (2.04–2.61 mmol/L), Q3 (2.61–3.21 mmol/L) and Q4 (>3.21 mmol/L). Patients with high baseline LDL-C levels were more likely to develop CI-AKI and composite end points including all-cause mortality, renal replacement therapy, non-fatal myocardial infarction, acute heart failure, target vessel revascularization or cerebrovascular accident during the observation period of hospitalization (8.9%, 9.9%, 10.5%, 12.6%, p = 0.001, and 5.0%, 5.2%, 6.1%, 8.1%, respectively; p = 0.007). Univariate logistic analysis showed that LDL-C levels (increment 1 mmol/L) were significantly associated with CI-AKI (odds ratio = 1.25, 95% confidence interval (CI), 1.11–1.39, p < 0.001). Furthermore, LDL-C remained a significant risk factor of CI-AKI (odds ratio = 1.23, 95% CI, 1.04–1.45, p = 0.014), even after adjusting for potential confounding risk factors. Conclusions: Measurement of plasma LDL-C concentrations in patients undergoing PCI may be helpful to identify those who are at risk of CI-AKI and poor in hospital outcomes.     

超声引导下喉上神经阻滞联合ZX-KSHJ可视喉镜在肥胖患者清醒气管插管中的应用效果

目的 探讨超声引导下喉上神经阻滞联合ZX-KSHJ可视喉镜在肥胖患者清醒气管插管中的应用效果。方法 选择2018年1月－2020年1月该院收治的120例拟行气管插管全身麻醉的肥胖患者作为研究对象,使用随机数表法将患者分为两组,每组各60例。观察组采用超声引导下喉上神经阻滞联合ZX-KSHJ可视喉镜气管插管,对照组采用超声引导下喉上神经阻滞联合传统光学喉镜气管插管。观察两组患者声门显露成功率、一次性气管插管成功率、总插管成功率、成功插管的平均插管时间、插管过程中呛咳发生率以及呛咳程度、血流动力学和插管相关并发症发生情况。结果 观察组声门显露成功率、一次性气管插管成功率高于对照组（P < 0.05）,成功插管的平均插管时间短于对照组（P < 0.05）,插管后1 min（T₁）和5 min（T₂）患者心率（HR）、无创收缩压（SBP）和无创舒张压（DBP）低于对照组（P < 0.05）,经皮动脉血氧饱和度（SpO₂）高于对照组（P < 0.05）,口腔出血、咽喉部损伤和气道损伤等并发症总发生率低于对照组（P < 0.05）。结论 超声引导下喉上神经阻滞联合ZX-KSHJ可视喉镜气管插管,可提高肥胖患者声门显露成功率和一次性插管成功率,缓解血流动力学波动,减少插管相关并发症发生风险。